Zhejiang Conba Pays $160.5 Million for Majority Stake in Baite Pharma

Zhejiang Conba Pharma will pay $160.5 million to acquire a 51% stake in Guizhou Baite Pharma. Both companies are involved in TCM products, though Conba also makes chemical drugs. The deal is, as Conba points out, its largest M&A transaction since it was listed. Baite’s major product is Danshen Chuanxiongqin injection, a blood thinner used to dissipate clots and treat strokes. More details.... Stock Symbol: (SHA: 600572) Share this with colleagues: // //